glp 1 month to month A real look at what progress can look like on a GLP-1 program ⚡️, This patient lost 25 lbs over the course of 6 months! Not overnight. Not extreme. Just consistent, steady progress., GLP-1 isn’t just Fitty GLP-1 Daily | Appetite,

Breakfast choices can make GI symptoms better or worse

Materials and methods Antibodies and reagents PC2 antibody (D1E1S), t-PKA antibody (D38C6), p-PKA antibody (D45D3), Pdx1 antibody (D59H3), GLP-1R antibody (HA500204) and all secondary antibodies used in Western blot were purchased from Cell Signaling Technology (Beverly, MA, United States)

Meta-analyses in diabetic populations have found a correlation between reductions in HbA1c and GLP-1RA-mediated MACE risk reduction.[37, 38] The SELECT trial, which enrolled patients without diabetes but with pre-existing cardiovascular disease (CVD) and a BMI 27, found a significant reduction in MACE among those treated with semaglutide, leading to FDA approval for MACE reduction in individuals with established CVD.[18, 39] A meta-analysis incorporating SELECT and other CVOTs concluded that GLP-1RAs provide a significant MACE reduction in individuals without diabetes, though the reduction in individuals with diabetes is more pronounced.[12] These findings of benefit in populations without diabetes suggest that while the antihyperglycemic effects of GLP-1RAs likely contribute to MACE reduction, other mechanisms, such as systolic blood pressure reduction, likely also play a role.[40] Over time, clinical trials on GLP-1RA MACE reduction have shifted from a focus on secondary prevention, with over 80% of participants in earlier trials such as LEADER and SUSTAIN 6 having a history of established cardiovascular disease, to an emphasis on primary prevention in high risk participants, with less than a third of participants in REWIND having a history of established cardiovascular disease.[8, 10, 11, 41] While semaglutide is currently only FDA-approved for secondary prevention of cardiovascular disease, a meta-analysis of GLP-1RA outcome trials found no significant difference in cardiovascular event relative risk reduction between use for primary versus secondary prevention

sin embargo, tambin han resultado extremadamente costosos

Sustainalytics dual-scoring Controversy research highlights how current market leaders Novo and Lilly are involved in a combined multi-district litigation over their GLP-1 drugs alleged link to gastrointestinal injuries, underscoring ongoing legal risks and associated impact safety risks

Front Immunol 14:1163288